Sanofi (EPA:SAN)
83.22
+0.10 (0.12%)
Jun 20, 2025, 5:36 PM CET
Sanofi Employees
Sanofi had 82,878 employees as of December 31, 2024. The number of employees decreased by 3,210 or -3.73% compared to the previous year.
Employees
82,878
Change (1Y)
-3,210
Growth (1Y)
-3.73%
Revenue / Employee
€544,970
Profits / Employee
€76,003
Market Cap
101.38B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
Dec 31, 2020 | 99,412 | -997 | -0.99% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
EssilorLuxottica Société anonyme | 153,498 |
Sartorius Stedim Biotech | 9,901 |
bioMérieux | 14,754 |
Eurofins Scientific SE | 62,696 |
Ipsen | 5,358 |
Virbac | 6,365 |
emeis Société anonyme | 83,494 |
Clariane SE | 61,798 |
Sanofi News
- 14 hours ago - BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC - Business Wire
- 22 hours ago - Regeneron, Sanofi win FDA label expansion for Dupixent against rare skin disorder - Seeking Alpha
- 1 day ago - Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease - WSJ
- 1 day ago - Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid - GlobeNewsWire
- 2 days ago - Sanofi Buys Blueprint: Smart Move Suits All Parties, Warrants A Rating Upgrade - Seeking Alpha
- 2 days ago - RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports - Reuters
- 2 days ago - RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury - CNBC
- 2 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY - GlobeNewsWire